BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23808106)

  • 1. [Prostate cancer in Luxembourg from 1982 to 2006. Incidence and mortality. Survival of a hospital cohort].
    Lamy S; Wilmart JF; Hein T; Scheiden R; Capesius C
    Bull Soc Sci Med Grand Duche Luxemb; 2013; (1):6-19. PubMed ID: 23808106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostatic cancer in the Grand Duchy of Luxembourg. Role of PSA].
    Lamy S; Hein T; Wilmart JF; Capesius C; Scheiden R; Gilson G; Humbel RL
    Bull Soc Sci Med Grand Duche Luxemb; 1998; 135(1):11-23. PubMed ID: 9868829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
    JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
    Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
    Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
    Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
    Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer.
    Petit JH; Chen MH; Loffredo M; Sussman B; Renshaw AA; D'Amico AV
    Cancer; 2006 Nov; 107(9):2180-5. PubMed ID: 17009323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer and prostate-specific antigen testing in New South Wales.
    Smith DP; Supramaniam R; Marshall VR; Armstrong BK
    Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
    Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
    BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
    Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
    Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
    D'Amico AV; Chen MH; Roehl KA; Catalona WJ
    N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
    Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study.
    Klemann N; Røder MA; Helgstrand JT; Brasso K; Toft BG; Vainer B; Iversen P
    Lancet Oncol; 2017 Feb; 18(2):221-229. PubMed ID: 28094199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study.
    Song P; Yang B; Peng Z; Zhou J; Ren Z; Fang K; Yang L; Wang L; Dong Q
    Int J Surg; 2020 Apr; 76():64-68. PubMed ID: 32109649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.